The search for a structural basis for therapeutic intervention against the SARS coronavirus
Identifieur interne : 003255 ( Main/Exploration ); précédent : 003254; suivant : 003256The search for a structural basis for therapeutic intervention against the SARS coronavirus
Auteurs : Mark Bartlam ; Xiaoyu Xue ; Zihe RaoSource :
- Acta Crystallographica Section A [ 0108-7673 ] ; 2008-01.
Descripteurs français
- KwdFr :
- Cysteine endopeptidases (), Modèles moléculaires, Protéines virales (), Protéines virales (antagonistes et inhibiteurs), Protéines virales structurales (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Vaccins antiviraux (immunologie), Virus du SRAS (), Virus du SRAS (ultrastructure).
- MESH :
- antagonistes et inhibiteurs : Protéines virales.
- immunologie : Vaccins antiviraux.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- Cysteine endopeptidases, Modèles moléculaires, Protéines virales, Protéines virales structurales, Virus du SRAS.
English descriptors
- KwdEn :
- Cysteine Endopeptidases (chemistry), Models, Molecular, SARS Virus (drug effects), SARS Virus (ultrastructure), Severe Acute Respiratory Syndrome (drug therapy), Viral Proteins (antagonists & inhibitors), Viral Proteins (chemistry), Viral Structural Proteins (chemistry), Viral Vaccines (immunology).
- MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemistry : Cysteine Endopeptidases, Viral Proteins, Viral Structural Proteins.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- chemical , immunology : Viral Vaccines.
- ultrastructure : SARS Virus.
- Models, Molecular.
Abstract
The 2003 outbreak of severe acute respiratory syndrome (SARS), caused by a previously unknown coronavirus called SARS‐CoV, had profound social and economic impacts worldwide. Since then, structure–function studies of SARS‐CoV proteins have provided a wealth of information that increases our understanding of the underlying mechanisms of SARS. While no effective therapy is currently available, considerable efforts have been made to develop vaccines and drugs to prevent SARS‐CoV infection. In this review, some of the notable achievements made by SARS structural biology projects worldwide are examined and strategies for therapeutic intervention are discussed based on available SARS‐CoV protein structures. To date, 12 structures have been determined by X‐ray crystallography or NMR from the 28 proteins encoded by SARS‐CoV. One key protein, the SARS‐CoV main protease (Mpro), has been the focus of considerable structure‐based drug discovery efforts. This article highlights the importance of structural biology and shows that structures for drug design can be rapidly determined in the event of an emerging infectious disease.
Url:
DOI: 10.1107/S0108767307054426
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000283
- to stream Istex, to step Curation: 000283
- to stream Istex, to step Checkpoint: 000F29
- to stream PubMed, to step Corpus: 001C46
- to stream PubMed, to step Curation: 001C46
- to stream PubMed, to step Checkpoint: 001986
- to stream Ncbi, to step Merge: 001B49
- to stream Ncbi, to step Curation: 001B49
- to stream Ncbi, to step Checkpoint: 001B49
- to stream Main, to step Merge: 003357
- to stream Main, to step Curation: 003255
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The search for a structural basis for therapeutic intervention against the SARS coronavirus</title><author><name sortKey="Bartlam, Mark" sort="Bartlam, Mark" uniqKey="Bartlam M" first="Mark" last="Bartlam">Mark Bartlam</name></author><author><name sortKey="Xue, Xiaoyu" sort="Xue, Xiaoyu" uniqKey="Xue X" first="Xiaoyu" last="Xue">Xiaoyu Xue</name></author><author><name sortKey="Rao, Zihe" sort="Rao, Zihe" uniqKey="Rao Z" first="Zihe" last="Rao">Zihe Rao</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:714886B4B69F05DFFFD19307666F5EE2C2C75CCF</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1107/S0108767307054426</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-SWBPGB6L-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000283</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000283</idno><idno type="wicri:Area/Istex/Curation">000283</idno><idno type="wicri:Area/Istex/Checkpoint">000F29</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F29</idno><idno type="wicri:doubleKey">0108-7673:2008:Bartlam M:the:search:for</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18156685</idno><idno type="wicri:Area/PubMed/Corpus">001C46</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C46</idno><idno type="wicri:Area/PubMed/Curation">001C46</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C46</idno><idno type="wicri:Area/PubMed/Checkpoint">001986</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001986</idno><idno type="wicri:Area/Ncbi/Merge">001B49</idno><idno type="wicri:Area/Ncbi/Curation">001B49</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B49</idno><idno type="wicri:doubleKey">0108-7673:2008:Bartlam M:the:search:for</idno><idno type="wicri:Area/Main/Merge">003357</idno><idno type="wicri:Area/Main/Curation">003255</idno><idno type="wicri:Area/Main/Exploration">003255</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The search for a structural basis for therapeutic intervention against the SARS coronavirus</title><author><name sortKey="Bartlam, Mark" sort="Bartlam, Mark" uniqKey="Bartlam M" first="Mark" last="Bartlam">Mark Bartlam</name></author><author><name sortKey="Xue, Xiaoyu" sort="Xue, Xiaoyu" uniqKey="Xue X" first="Xiaoyu" last="Xue">Xiaoyu Xue</name></author><author><name sortKey="Rao, Zihe" sort="Rao, Zihe" uniqKey="Rao Z" first="Zihe" last="Rao">Zihe Rao</name></author></analytic><monogr></monogr><series><title level="j" type="main">Acta Crystallographica Section A</title><title level="j" type="alt">ACTA CRYSTALLOGRAPHICA A</title><idno type="ISSN">0108-7673</idno><idno type="eISSN">1600-5724</idno><imprint><biblScope unit="vol">64</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="204">204</biblScope><biblScope unit="page" to="213">213</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>5 Abbey Square, Chester, Cheshire CH1 2HU, England</pubPlace><date type="published" when="2008-01">2008-01</date></imprint><idno type="ISSN">0108-7673</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0108-7673</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cysteine Endopeptidases (chemistry)</term><term>Models, Molecular</term><term>SARS Virus (drug effects)</term><term>SARS Virus (ultrastructure)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viral Proteins (chemistry)</term><term>Viral Structural Proteins (chemistry)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cysteine endopeptidases ()</term><term>Modèles moléculaires</term><term>Protéines virales ()</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Protéines virales structurales ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (ultrastructure)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Viral Proteins</term><term>Viral Structural Proteins</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Models, Molecular</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Modèles moléculaires</term><term>Protéines virales</term><term>Protéines virales structurales</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 2003 outbreak of severe acute respiratory syndrome (SARS), caused by a previously unknown coronavirus called SARS‐CoV, had profound social and economic impacts worldwide. Since then, structure–function studies of SARS‐CoV proteins have provided a wealth of information that increases our understanding of the underlying mechanisms of SARS. While no effective therapy is currently available, considerable efforts have been made to develop vaccines and drugs to prevent SARS‐CoV infection. In this review, some of the notable achievements made by SARS structural biology projects worldwide are examined and strategies for therapeutic intervention are discussed based on available SARS‐CoV protein structures. To date, 12 structures have been determined by X‐ray crystallography or NMR from the 28 proteins encoded by SARS‐CoV. One key protein, the SARS‐CoV main protease (Mpro), has been the focus of considerable structure‐based drug discovery efforts. This article highlights the importance of structural biology and shows that structures for drug design can be rapidly determined in the event of an emerging infectious disease.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Bartlam, Mark" sort="Bartlam, Mark" uniqKey="Bartlam M" first="Mark" last="Bartlam">Mark Bartlam</name><name sortKey="Rao, Zihe" sort="Rao, Zihe" uniqKey="Rao Z" first="Zihe" last="Rao">Zihe Rao</name><name sortKey="Xue, Xiaoyu" sort="Xue, Xiaoyu" uniqKey="Xue X" first="Xiaoyu" last="Xue">Xiaoyu Xue</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003255 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003255 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:714886B4B69F05DFFFD19307666F5EE2C2C75CCF
|texte= The search for a structural basis for therapeutic intervention against the SARS coronavirus
}}
| This area was generated with Dilib version V0.6.33. |  |